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Abstract The 7th Ammendment to the Cosmetics
Directive of the European Commission (Directive 76/
768/EEC2) bans the marketing of cosmetics containing
animal-tested ingredients since March 2009. Excepted
are only tests for repeated dose toxicity, for which the
animal ban will come into effect by 2013. One major
concern for cosmetics, i.e. the risk of containing skin
(contact) sensitizers, has in the past been addressed
almost exclusively by animal testing. It is this problem
attracting the central interest of the integrated research
project Sens-it-iv (Novel Testing Strategies for in vitro
Assessment of Allergens, http://www.sens-it-iv.eu), fun-
ded by the EC within framework 6 since October 2005.
Here, the 28 Sens-it-iv partners from 10 European States
present the 5 most promising types of in vitro assays
selected for further refinement. These are: (1) a human
epidermal equivalent (EE) model to rank contact aller-
gens according to their sensitizing potency, (2)
identification of contact sensitizers, including pro-
haptens, through intracellular production of IL-18 by
the human keratinocyte cell line NCTC 2544, (3) deter-
minationof activationmarkers such asCD86, CD54 and
most prominently CXCL8 (IL-8) on/in dendritic cell lines,
(4) contact sensitizer-specific migration of MUTZ Lan-
gerhans cells towards the chemokine CXCL12, and (5)
the allergen-specific activation and proliferation of
naı¨ve human Tcells. Ongoing genomic and proteomic
experiments are in the process of identifying larger
sensitizer-specific biological marker signatures to be
integrated into the above assays.Wehope to supply the
European control agencies with a basis for further val-
idation of in vitro assays by the end of 2010.
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untersagt seit Ma¨rz 2009 den Verkauf von Kosmetika,
deren Bestandteile in Tierexperimenten getestet
wurden. Einzige Ausnahme sind Tests auf ‘‘repeated
dose toxicity’’, fu¨r die das Verbot erst 2013 in Kraft
tritt. Ein besonders fu¨r Kosmetika-Zusa¨tze wichtiges,
und bislang nur in Tierversuchen gepru¨ftes,
Gesundheitsrisiko liegt in der Sensibilisierung fu¨r
Kontaktallergien. Das seit Oktober 2005 im 6.
Rahmenprogramm der EU gefo¨rderte integrierte
Forschungsprojekt Sens-it-iv (Novel Testing Strategies
for in vitro Assessment of Allergens, http://www.
sens-it-iv.eu) konzentriert sich besonders auf dieses
Problem. Die 28 Partner aus 10 europa¨ischen Staaten
pra¨sentieren hier fu¨nf erfolgversprechende Typen
von in vitro Testverfahren, die fu¨r die weitere
Entwicklung ausgewa¨hlt wurden. Es sind dies (1) ein
Toxizita¨tstest am Epidermal Equivalent (EE) Modell,
der die Quantifizierung der allergenen Wirkung von
Testsubstanzen erlaubt, (2) die Induktion von IL-18 in
der Keratinozytenline NCTC 2544, mit welcher
speziell Kontaktallergene, inklusive der sogenannten
Prohaptene, entdeckt werden, (3) der Nachweis von
Aktivierungsmarkern wie CD86, CD54 oder vor allem
CXCL8 (IL-8) auf/in dendritischen Zell-Linien, (4)
ein Migrationstest, der auf allergeninduzierter
Wanderung von MUTZ Langerhans Zellen in
Richtung des Chemokins CXCL12 beruht und (5) die
Allergen-spezifische Aktivierung und Proliferation
humaner T-Zellen. Laufende genomische und
proteomische Großexperimente zielen auf die
Definition zusa¨tzlicher allergenspezifischer Marker
-Signaturen, welche in die obigen Tests integriert
werden ko¨nnen. Bis Ende 2010 hoffen wir den
europa¨ischen und nationalen Kontrollbeho¨rden
Grundlagen fu¨r Validierungsverfahren liefern zu
ko¨nnen.
1 Introduction
The European Directive 86/609/EEC and the 7th
Amendment to the Cosmetics Directive enforce an
animal testing ban for all cosmetic ingredients since
March 2009. Moreover, a marketing ban is in force for
cosmetic products containing ingredients tested in
animals for all endpoints except repeated dose toxicity,
for which the deadline is 2013. Considerable efforts
have therefore been initiated to develop in vitro alter-
natives for risk assessment (Hartung 2009), including
the identification of potential allergenic sensitizers.
One such effort is the European FP6 Integrated Project
Sens-it-iv (1.10.2005–30.9.2010), entitled Novel Testing
Strategies for in vitro Assessment of Allergens (http://
www.sens-it-iv.eu). In vitro methods, despite persisting
difficulties to completely simulate an in vivo immune
system, have the advantage of circumventing inter-
species differences by concentrating exclusively on
human cell material. However, as yet validated in vitro
alternatives are lacking, raising questions about the
future safety of cosmetics. While final answers to this
question have to come fromnational and international
regulatory authorities, the scientific basis is tobe laidby
basic and applied research, not last within the Sens-it-iv
consortium. It’s 28 partners from academia, industry
and special interest organizations focus on the in vitro
identification of both, respiratory and skin sensitizers,
but in the context of cosmeticswewill here concentrate
on our work concerning skin sensitization.
2 The Sens-it-iv concept
Sens-it-iv divides its efforts into a science (basic) and
a technology (applied) module (Fig. 1). During the
Fig. 1 Work package
organization of the Sens-it-iv
consortium. The science
module concentrates on basic
understanding of lung and
skin sensitization and
characterization of the
cellular components. EC
epithelial cells, DC dendritic
cells. After month 36 activities
are increasingly transferred to
the technology module with
WP8 concentrating on the
development of practical
assays
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‘basic research’ phase (01.10.2005–30.09.2008),
improved appreciation was obtained of the biologi-
cal processes involved in the exposure of tissue to
sensitizing materials. Within the ‘applied research’
phase (01.10.2008–30.09.2010) information of the sci-
ence module is used to develop and standardize assay
systems, which model sensitization of chemicals and
proteins.
These activities are divided into nine work pack-
ages (WP) with WP1 laying the grounds by providing
standardized samples and handling procedures of a
list of tutorial chemicals, including respiratory and
skin sensitizers, irritants and controls (list available
under http://www.sens-it-iv.eu). WP2 and WP3
address the different cell types involved in sensitiza-
tion as well as their mutual interactions, and WPs 4–6
deal with identifying new markers or metabolic
pathways, respectively. The most promising assays
were transferred into WP8 of the technology module
to select the best cell lines and assure reproducibility
between different laboratories, and those tests will be
discussed below. WP progress is monitored in
monthly newsletters under http://www.sens-it-iv.eu.
3 Skin sensitization in vivo and corresponding
predictive in vitro assays
The major steps in the sensitization for contact sen-
sitivity (Karlberg et al. 2008) are indicated in Fig. 2.
Chemical allergens after penetration of the stratum
corneum bind either directly (haptens) or upon
metabolic transformation (pro-haptens) to proteins
in the epidermis. Uptake and processing of these
modified proteins by epidermal Langerhans cells (LC)
is followed by maturation and migration of LC
towards the draining lymph node where they acti-
vate allergen-specific T cells. The Sens-it-iv approach
has dissected this process into several assays, which
are also indicated in Fig. 2.
The first one mimics the penetration of the stra-
tum corneum and general irritation of epidermal
cells. The second refers to sensitizer-specific respon-
ses of epidermal keratinocytes. Tests of type number
3 study the induction of maturation markers on
dendritic cells (DC) and corresponding human cell
lines, and test number 4 addresses the induction of
LC migration. Tests 5 and 6, finally, deal with activa-
tion and proliferation of T cells specific for individual
sensitizing chemicals. While the latter assays are by
nature not made to screen large panels of chemicals,
they will be particularly helpful in determining the
immunological responsiveness of humans to selected
allergens.
4 The EE potency assay
To determine the allergenic potency of chemicals
we developed a 3-dimensional epidermal-equivalent
model (EE), which can be constructed from foreskin
keratinocytes (Spiekstra et al. 2009). The great
advantage of this model is that chemicals, inde-
pendent of their solubility in water may be topically
Fig. 2 Major steps in skin
sensitization and
corresponding in vitro assays.
Tests 1–6 (right) address
different processes in the
cause of skin sensitization
(left)
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applied on the very same type of filter discs used in
human patch testing. The readout is metabolic cell
activity by the MTT color reaction and calculation of
EC50 values (i. e. the concentration leading to 50%
reduction of metabolic activity). This assay cannot
differentiate irritants from allergens. However,
when selectively applied to sensitizers identified by
any of the other assays below, the majority of EC50
values correlates well with EC3 data derived in vivo
by LLNA testing (Fig. 3), allowing a classification
into strong, intermediate and weak sensitizers.
Interestingly, none of the respiratory sensitizers
tested so far was active in this assay (Spiekstra et al.
2009).
5 Interleukin 18 (IL-18) production by keratinocytes
Several years ago van Och et al. (2005) reported that
human keratinocytes responded to sensitizers by
increased production of IL-18. In our current view this
may reflect a cleavage of inactive IL-18 precursor via
activation of inflammasome located caspase 1
(Martinon et al. 2009). Determining intracellular IL-18
in the human keratinocyte cell line NCTC 2544
(Corsini et al. 2009) we now established an assay,
which correctly detected all contact sensitizers of
the Sens-it-iv tutorial chemicals (including the pro-
haptens eugenol, isoeugenol, cinnamic alcohol and
paraphenylenediamine), and neither reacted to irri-
tants nor to respiratory sensitizers (for examples see
Fig. 4). A research proposal to pre-validate this
approach is currently being submitted to ZonMW,
The Netherlands.
6 Maturation markers on dendritic cells
Human dendritic cells can be prepared from peri-
pheral blood monocytes (MoDC) in various maturation
states. However, besides restricted lifetime and
differences between individual donors also
interlaboratory variation in the preparations may be
significant. Established DC-like human cell lines such
as THP-1, U937 or MUTZ-3 may overcome some of
these problems (dos Santos et al. 2009), but on the
other hand are even less likely to completely resemble
all properties of DCs in vivo. A genomic comparison of
different DCs and DC lines revealed significant dif-
ferences in gene expression between all these cells,
but identified MUTZ-3 as the cell line of relative clos-
est similarity to in vivo conditions (Borrebaeck et al.
unpublished). This and the fact that depending on
culture conditions MUTZ-3 cells may be obtained in a
variety of DC-typical maturation states, including LC-
like properties, made MUTZ-3 cells to the preferred
DC line in our studies. Nevertheless, many experi-
ments also include THP-1 or U937 cells (Python et al.
2009) and an ongoing ring trial in different labora-
tories compares their suitability in our various assays.
A number of sensitizer-specific maturation mar-
kers on DCs have been described such as the
membrane proteins CD86 and CD54 (Python et al.
2009), the signaling protein p38 (Mitjans et al. 2008),
or the secretion of interleukin 8 (IL-8, CXCL8) (Toebak
et al. 2009), with the latter one found to be among
the most promising in our hands. Figure 5 shows
representative examples for IL-8 responses by MUTZ-3
cells to three different sensitizers and three
non-sensitizers.
Fig. 3 Epidermal equivalent (EE) potency assay (Spiekstra et al.
2009): correlation with LLNA. EE in double chamber cultures are
topically exposed to chemicals via patch filters (left). After 24 h
metabolical activity of the cultures is determined by MTT assay.
Concentrations for 50% reduction of metabolic activity (EC50
values) are deduced graphically and compared to EC3 values
reported for the same chemicals for local lymph node assays
(LLNA) (right)
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Fig. 4 NCTC IL-18 assay
(Corsini et al. 2009). Sub-
confluent cultures of NCTC
2544 cells were treated for
24 h with increasing non-
cytotoxic concentrations of
the selected chemicals. Cells
incubated with vehicle served
as control (0). Cell-associated
IL-18 was determined by ELISA
in cell lysates. Figures show
dose response effects of two
contact sensitizers
(cinnamaldehyde, a and
isoeugenol, b) two respiratory
allergens (maleic
anhydride, c and
hexamethylenediisocyanate,
d), and two irritants (lactic
acid, e and salycilic acid, f).
Note different y-scales for A
and B. IL-18 data are shown as
pg per mg of total lysate
protein. Results are expressed
as mean ± SD, n = 4.
Statistical analysis was
performed with Dunnett’s
multiple comparison test,
with *P\0.05 and **P\0.01
versus vehicle treated cells (0)
Fig. 5 CXCL8 (IL-8) secretion
from MUTZ-3 cells. Data
exemplify dose dependent
secretion of IL-8 by MUTZ-3
cells for two sensitizers (DNCB
and cinnamaldehyde) and
two irritants (salycilic acid and
phenol). CXCL8 is expressed
as ng per 106 cells
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7 LC/DC migration assay
To simulate hapten-induced migration of LC from the
epidermis to the dermis, a dual chamber experiment
was designed. Fluorescently labeled (CSFE) MUTZ-LC
in the upper compartment of a well will migrate
through a porous filter toward fibroblasts growing
on the bottom of the lower chamber where they may
be collected and quantified. This migration depends
on two fibroblast-derived chemokines, i.e. CXCL12
(Ouwehand et al. 2008) and CCL5 (manuscript sub-
mitted). Replacement of fibroblasts in the lower
chamber by either of the two chemokines effectively
retains this directed mobility. Pre-treatment of MUTZ-
LC with sensitizers, but not with irritants induces the
expression of a CXCL12 receptor and, hence, enhan-
ces migration towards CXCL12 without affecting
CCL5 dependent migration. For every chemical the
index of migration directed towards CXCL12 versus
that directed towards CCL5 can be determined. An
index of CXCL12:CCL5[ 1, therefore, indicates sensi-
tizers, values\ 1 non-sensitizers.
8 T cell priming assay
The final step of the sensitization phase in contact
dermatitis is the activation of naı¨ve T cells in the local
lymph node. This step creates the remarkable struc-
tural specificity in the eventual elicitation phase by
selecting and activating a minute fraction within the
pool of available T cells. Each of these few cells carries
a different, though functionally similar T cell antigen
receptors (TCR) allowing a complementary fit to
complexes of hapten-modified self-peptides and self-
MHC molecules on the surface of DC or other antigen
presenting cells (Weltzien et al. 1996; Martin 2004).
Our in vitro T cell priming assay employs MoDCs
and sorted naı¨ve T cells depleted of the CD25? re-
gulatory (suppressive) subpopulation of the same
donor. MoDCs when modified by direct interaction
with haptens or alternatively with hapten-protein
adducts in co-culture drive hapten-specific T cells
into proliferation and differentiation to produce
interleukins such as interferon gamma (IFN-g).
Combination with a polyclonal T cell amplification
step (Geiger et al. 2009) before the addition of spe-
cific allergen can significantly increase the sensitivity
of the system and allows for frequency determination
of T cells of extremely rare specificities as well as
for isolation and functional/genetical analysis of
allergen-specific T cell clones.
As mentioned above, such assays may yield valu-
able information in situations not satisfactory
clarified by other tests, while clearly not being
developed for high throughput screening.
9 ‘‘-Omics’’ Technologies
All assays described above make use of maximally
two or three marker molecules. Given the large
number of potentially sensitizing chemicals and the
different routes of their interaction with the immune
system, significantly larger ‘‘signatures’’ of biological
markers of allergenic stimulation may be required
Fig. 6 Protein classification using partial least square (PLS)
regression. Proteome-wide changes induced by chemical aller-
gens in primary human keratinocytes were studied by TMT-
based mass spectrometry (Schrader et al. 2006). PLS was used to
classify chemicals based on cellular protein expression profiles.
The analysis was carried out by encoding the experimental
design (compounds and concentration) as Y-response vectors
and the referenced protein abundance values of 153 proteins as
X-vectors. Components 1 and 2 separate the samples into the
three experimental groups. Filled squares allergens, gray squares
controls, open circles irritants
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for effective risk assessment. Large genomic and
proteomic data sets of allergen- and control-treated
DCs and keratinocytes, partially obtained in parallel
from the same experiments, are in the process of
being analysed. Preliminary results from both groups
of data reveal encouraging marker separations into
sensitizer, irritant or control specific clusters (Figs. 6,
7). The time-lag between assay performance and the
eventual supply of additional indicative markers has
been bridged by freezing culture supernatants and
RNA samples from most test models under study. In
this way all materials may later be assayed for newly
defined markers on RNA and/or protein level.
10 Conclusions
The EU ban of animal experiments for risk assess-
ment of cosmetics by the 7th Amendment to the
Cosmetics Directive has induced widespread activi-
ties in search for in vitro alternatives. There is general
consensus that a combination of several functionally
distinct human-based in vitro strategies can be suc-
cessful and may eventually even surpass the accuracy
of animal experiments. Following this route, several
mechanistically relevant and promising test-strate-
gies have been developed within the Sens-it-iv project
and are being further refined. We see realistic
chances to refine some of these assays to the stage
where they can be formally evaluated and validated.
The timing, however, to get these new technologies
accepted by regulatory and legislative bodies lies
outside the influence of Sens-it-iv. In that sense an
answer to the original question concerning the
future safety of cosmetics may depend on necessary
interim solutions enforced by regulatory authorities.
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